Search
Search
About
Log in
Join
Experiences with
Abiraterone
Posts
Communities
1,280 public posts
Filter results
It's Half Time at the Chemo Bowl - I am in front right now
MO advises that next treatments are likely to be hormonal -
abiraterone
or enzalutamide I guess. But since I am already hormone-independent I don't know how much this will help. Since I failed ADT within 3 months I asked MO if I have ARV7 splice variant.
MO advises that next treatments are likely to be hormonal -
abiraterone
or enzalutamide I guess. But since I am already hormone-independent I don't know how much this will help. Since I failed ADT within 3 months I asked MO if I have ARV7 splice variant.
Hazard
in
Advanced Prostate Cancer
6 years ago
Phase II Study of Low-Dose Abiraterone With Food.
term=
Abiraterone
+Szmulewitz&rank=1
term=
Abiraterone
+Szmulewitz&rank=1
pjoshea13
in
Advanced Prostate Cancer
6 years ago
[177Lu]-PSMA-617 Has Activity in Castration-Resistant Prostate Cancer
Hofman, Violet, and colleagues evaluated the efficacy and safety of LuPSMA in a prospective phase II trial of 30 patients with metastatic castration-resistant prostate cancer who had progressed after standard therapies including taxane-based chemotherapy and second-generation antiandrogens (
abiraterone
Hofman, Violet, and colleagues evaluated the efficacy and safety of LuPSMA in a prospective phase II trial of 30 patients with metastatic castration-resistant prostate cancer who had progressed after standard therapies including taxane-based chemotherapy and second-generation antiandrogens (
abiraterone
tango65
in
Advanced Prostate Cancer
6 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Yonsa vs Zytiga
20News%205-24-18&utm_content=CURE%20Breaking%20News%205-24-18+CID_2c56c8562f2ebb7c4451afd760438ae8&utm_source=Campaign%20Monitor&utm_term=Read%20full%20story FDA Approves Combination Treatment for Metastatic Prostate Cancer The Food and Drug Administration (FDA) approved a new formulation of Yonsa (
abiraterone
20News%205-24-18&utm_content=CURE%20Breaking%20News%205-24-18+CID_2c56c8562f2ebb7c4451afd760438ae8&utm_source=Campaign%20Monitor&utm_term=Read%20full%20story FDA Approves Combination Treatment for Metastatic Prostate Cancer The Food and Drug Administration (FDA) approved a new formulation of Yonsa (
abiraterone
JLS1
in
Advanced Prostate Cancer
6 years ago
Non Standard of Care Advice!
Went on Lupron and Casodex end of March 2017, and switched to Lupron and
Abiraterone
in August, 2017. My PSA and T have been 0 ever since. Based on advice from this board, i opted (found a very good surgeon) who performed a RP end of January 2017.
Went on Lupron and Casodex end of March 2017, and switched to Lupron and
Abiraterone
in August, 2017. My PSA and T have been 0 ever since. Based on advice from this board, i opted (found a very good surgeon) who performed a RP end of January 2017.
Stickingaround1
in
Advanced Prostate Cancer
6 years ago
Neutrophil-to-Lymphocyte ratio [NLR] & Abiraterone.
KEYWORDS: CRPC; NLR;
abiraterone
acetate PMID: 29541468 PMCID: PMC5838297 DOI: 10.3892/mco.2018.1573
KEYWORDS: CRPC; NLR;
abiraterone
acetate PMID: 29541468 PMCID: PMC5838297 DOI: 10.3892/mco.2018.1573
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Olaparib/Durvalumab Combo Shows Promise in mCRPC
Some 94% had received treatment previously with enzalutamide, 65% with
abiraterone
, and 59% with both agents. Almost half (47%) had prior immunotherapy and 65% had prior chemotherapy. Eighty-two percent had an ECOG performance status of 1.
Some 94% had received treatment previously with enzalutamide, 65% with
abiraterone
, and 59% with both agents. Almost half (47%) had prior immunotherapy and 65% had prior chemotherapy. Eighty-two percent had an ECOG performance status of 1.
JLS1
in
Advanced Prostate Cancer
6 years ago
Bone care
At present PSA 0.22, after 6 months treatment with
ABIRATERONE
. It seems that there is a lot of bone spread. How are you looking after your bones? Any advice?
At present PSA 0.22, after 6 months treatment with
ABIRATERONE
. It seems that there is a lot of bone spread. How are you looking after your bones? Any advice?
joancarles
in
Advanced Prostate Cancer
6 years ago
Need some help
I then restarted
Abiraterone
and had a good drop in PSA after 2 weeks but then i had three consecutive increases and
Abiraterone
has now been stopped with my PSA at 5 So my question is i have been offered treatment that i can not find much information on here in the UK and was after your thoughts, so
I then restarted
Abiraterone
and had a good drop in PSA after 2 weeks but then i had three consecutive increases and
Abiraterone
has now been stopped with my PSA at 5 So my question is i have been offered treatment that i can not find much information on here in the UK and was after your thoughts, so
siness
in
Advanced Prostate Cancer
6 years ago
I am new here, I am from Australia, I have extensive mets.
I will start
abiraterone
and pred. after the rays. Anyone else had LU PSMA in similar circumstances?
I will start
abiraterone
and pred. after the rays. Anyone else had LU PSMA in similar circumstances?
Metungboy
in
Advanced Prostate Cancer
6 years ago
Is AR-V7 Testing Pointless?
Neither
abiraterone
nor enzalutamide can have therapeutic activity against AR-V7 cells.
Neither
abiraterone
nor enzalutamide can have therapeutic activity against AR-V7 cells.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Ralaniten [EPI-506]
anti-androgens mentions Ralaniten (aka EPI-506) as a: "novel first-in-class drug ... which binds to a unique region in the N-terminus domain of both the full-length and the truncated constitutively active splice variants of the AR, {&} is currently in clinical trials for patients who previously received
abiraterone
anti-androgens mentions Ralaniten (aka EPI-506) as a: "novel first-in-class drug ... which binds to a unique region in the N-terminus domain of both the full-length and the truncated constitutively active splice variants of the AR, {&} is currently in clinical trials for patients who previously received
abiraterone
pjoshea13
in
Advanced Prostate Cancer
6 years ago
What is mCRPC
The proper categorization matters because I am eligible for the
abiraterone
olaparib trial if I am castration resistant. Has anyone else been down this road? Any thoughts on how I should be categorized?
The proper categorization matters because I am eligible for the
abiraterone
olaparib trial if I am castration resistant. Has anyone else been down this road? Any thoughts on how I should be categorized?
ewhite999
in
Advanced Prostate Cancer
6 years ago
Abiraterone effectiveness time
My first treatment is for ADT and
Abiraterone
. I would like to know about experiences with Abiraterona. And times of effectiveness. A hug to everyone and a lot of luck
My first treatment is for ADT and
Abiraterone
. I would like to know about experiences with Abiraterona. And times of effectiveness. A hug to everyone and a lot of luck
joancarles
in
Advanced Prostate Cancer
6 years ago
Positive mind and advanced prostate cancer
The truth is, the treatment of ADT +
Abiraterone
is working well. I have no pain, I have taken weight and my PSA has dropped from 1350, at the time of diagnosis, to 0.2 in the last revision. My oncologist tells me that everything is going very well.
The truth is, the treatment of ADT +
Abiraterone
is working well. I have no pain, I have taken weight and my PSA has dropped from 1350, at the time of diagnosis, to 0.2 in the last revision. My oncologist tells me that everything is going very well.
joancarles
in
Advanced Prostate Cancer
6 years ago
Docetaxel for Prostate Cancer: 'Win-Win-Win'Nick Mulcahy
How Does This Compare to
Abiraterone
? The new data prompted Sumanta K.
How Does This Compare to
Abiraterone
? The new data prompted Sumanta K.
Hidden
in
Advanced Prostate Cancer
6 years ago
SPARTAN (Apalutamide)
Note that
Abiraterone
Acetate (Zytiga) is a steroidal CYP17A1 inhibitor - not a direct androgen receptor [AR] inhibitor. The confusion is probably due to the fact that hormonal therapy in all its forms ultimately targets AR.
Note that
Abiraterone
Acetate (Zytiga) is a steroidal CYP17A1 inhibitor - not a direct androgen receptor [AR] inhibitor. The confusion is probably due to the fact that hormonal therapy in all its forms ultimately targets AR.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Recent article about Lutetium 177 treatment in advanced mCRPC by doctors at the Technical University of Munich
Eligibility criteria for 177Lu-PSMA-I&T therapy included previous treatment with
abiraterone
or enzalutamide, previous taxane-based chemotherapy or unsuitability for taxanes as well as positive 68Ga-PSMA tracer uptake of metastases in a prior PET-scan.
Eligibility criteria for 177Lu-PSMA-I&T therapy included previous treatment with
abiraterone
or enzalutamide, previous taxane-based chemotherapy or unsuitability for taxanes as well as positive 68Ga-PSMA tracer uptake of metastases in a prior PET-scan.
Hidden
in
Advanced Prostate Cancer
6 years ago
How late is too late for Abiraterone?
This is important as there is a small (miniscule) chance that the NHS will agree later this year that
Abiraterone
should be given as standard front line treatment (it is under review by Govt).
This is important as there is a small (miniscule) chance that the NHS will agree later this year that
Abiraterone
should be given as standard front line treatment (it is under review by Govt).
Jlcwonderboy
in
Advanced Prostate Cancer
6 years ago
Interesting result for BRCA patients from ASCO2018
"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line
abiraterone
and enzalutamide."
"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line
abiraterone
and enzalutamide."
snoraste
in
Advanced Prostate Cancer
6 years ago
1
...
58
59
60
...
64
Next page
10
20
30
40
50
60
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1204 results
Fight Prostate Cancer
50 results
Prostate Cancer Network
9 results
View top 10 communities
Sort by
Most Relevant
Newest